



March 14, 2013

**Health Canada  
Address Locator 0900C2  
Ottawa, Ontario  
K1A 0K9**

Dear Sir or Madame,

On behalf of those concerned by the withdrawal of Catena<sup>®</sup> (Idebenone), we request that you keep Catena<sup>®</sup> (Idebenone) on the Canadian market.

Several individuals with Friedreich's ataxia have experienced the drug's health benefits on themselves, their child or another family member. Until now, ataxic patients have relied on Catena<sup>®</sup> (Idebenone), the only drug of its kind, as their only hope for a treatment. For most of these patients, the drug's withdrawal has caused much distress and led them to feel as though they have been completely abandoned, since Friedreich's ataxia's is a fatal degenerative disease, with no treatment.

Therefore, CAFA supports the requests of those affected by this situation, by addressing Health Canada in an effort to make Catena<sup>®</sup> (Idebenone) available through a special access program.

Sincerely,

Jean Phenix, CAFA board member